Health Technology Takeda Pharmaceutical Co., Ltd. Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2023
JPY USD Revenue 4,027.47B 29,719.25M Gross Profit 2,298.31B 16,959.55M Operating income 658,291M 4,857.61M Income before tax 383,720M 2,831.51M Net income 317,017M 2,339.30M EBITDA 1,322.69B 9,760.29M Diluted EPS 201.93 1.49 Dividends Per Share 180 1.32 Total Assets 13,957.75B 104,874.52M Total liabilities 7,603.08B 57,127.35M Total equity 6,354.12B 47,743.04M Operating cash flow 877,217M 6,473.09M Currency in JPY Currency in USD
Historical Data Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
2,097.22B
3,291.18B
3,197.81B
3,569.00B
4,027.47B
Gross Profit
1,275.55B
1,789.37B
1,798.37B
2,043.63B
2,298.31B
Operating income
218,686M
302,612M
447,610M
610,496M
658,291M
Income before tax
127,612M
-60,754M
366,159M
317,938M
383,720M
Net income
135,192M
44,241M
376,005M
230,059M
317,017M
EBITDA
466,377M
886,261M
1,007.28B
1,193.64B
1,322.69B
Diluted EPS
139.82
28.24
238.95
145.86
201.93
Dividends Per Share
180
180
180
180
180
Total Assets
13,792.77B
12,821.09B
12,912.29B
13,178.01B
13,957.75B
Total liabilities
8,606.78B
8,093.60B
7,735.11B
7,494.49B
7,603.08B
Total equity
5,181.98B
4,723.48B
5,173.03B
5,683.01B
6,354.12B
Operating cash flow
302,609M
555,410M
905,073M
1,021.21B
877,217M
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Revenue
18,911.85M
30,270.54M
30,151.70M
31,760.44M
29,719.25M
Gross Profit
11,502.42M
16,457.72M
16,956.61M
18,186.20M
16,959.55M
Operating income
1,972.01M
2,783.25M
4,220.44M
5,432.77M
4,857.61M
Income before tax
1,150.74M
-558.78M
3,452.46M
2,829.31M
2,831.51M
Net income
1,219.10M
406.90M
3,545.29M
2,047.28M
2,339.30M
EBITDA
4,205.58M
8,151.34M
9,497.50M
10,622.21M
9,760.29M
Diluted EPS
1.26
0.25
2.25
1.29
1.49
Dividends Per Share
1.62
1.65
1.69
1.60
1.32
Total Assets
124,612.85M
118,763.31M
116,853.33M
108,572.75M
104,874.52M
Total liabilities
77,759.25M
74,972.05M
70,001.05M
61,746.62M
57,127.35M
Total equity
46,817.41M
43,754.18M
46,814.81M
46,821.99M
47,743.04M
Operating cash flow
2,728.79M
5,108.35M
8,533.80M
9,087.77M
6,473.09M
Valuation Measures
Mar 2023
PER 21.29 ROA 2.33% ROE 5.26% Operating margin 16.34% Profit margin 7.87%
Management
President, CEO & Director:
Christophe Weber
Chief Financial Officer & Director:
Constantine Saroukos
Director, President-Research & Development:
Andrew S. Plump
Chief Medical & Scientific Officer:
Michael E. Mendelsohn
Chief Data & Technology Officer:
Gabriele Ricci Shareholders
Nomura Asset Management Co., Ltd. (4.3%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
The Vanguard Group, Inc. (3.3%)
BlackRock Fund Advisors (2.0%)
Nikko Asset Management Co., Ltd. (2.0%)
Daiwa Asset Management Co. Ltd. (2.0%)
Nippon Life Insurance Co. (1.7%)
Capital International Ltd. (1.7%)
Norges Bank Investment Management (1.5%)
Capital Research & Management Co. (Global Investors) (1.4%)
Related Companies
Nimbus Lakshmi, Inc.
Takeda Digital Ventures
Takeda Pharmaceutical Employee Long Term Incentive Plan
Takeda Dunboyne Biologics Ltd.
Plasmaspendedienst GmbH
Takeda Belgium NV
Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
Adaptate Biotherapeutics Ltd.
Takeda Re Insurance AG
Plasmapunkt Favoriten GmbH
Takeda Malaysia Sdn. Bhd.
Takeda Pharmaceutical Co. Ltd. /Latam Bus/
Takeda Oranienburg Real Estate GmbH & Co. KG
Pvp Biologics, Inc.
Maverick Therapeutics, Inc.
Gammadelta Therapeutics Ltd.
Takeda Pharmaceutical Director Incentive Plan
Takeda Pharmaceutical Employee Incentive Plan
Oy Leiras Takeda Pharmaceuticals AB
Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
Takeda Pharma AB
Takeda Development Center Americas, Inc.
Takeda Ukraine LLC
Takeda Pharmaceuticals Taiwan Ltd.
Takeda SRL
Takeda Hellas SA
Takeda Christiaens SCA/CVA
Takeda Belgium SCA/CVA
Takeda Vaccines Pte Ltd.
Takeda Development Center Asia Pte Ltd.
Competitors
AstraZeneca PLC
CSL Limited
Grifols, S.A. Class A
Amgen Inc.
Green Cross Corporation
Novo Nordisk A/S Class B
Protalix Biotherapeutics, Inc.
Galapagos NV
BioMarin Pharmaceutical Inc.
Amicus Therapeutics, Inc.
Pharming Group NV
ADMA Biologics, Inc.
Novartis AG
Pfizer Inc.
Sanofi
Johnson & Johnson
Eisai Co., Ltd.
AbbVie, Inc.
Bristol-Myers Squibb Company
Organon & Co.
Merck & Co., Inc.
Roche Holding Ltd Dividend Right Cert.
Bayer AG
Swedish Orphan Biovitrum AB
Gilead Sciences, Inc.
Karyopharm Therapeutics, Inc.
ISU Abxis Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
Supernus Pharmaceuticals, Inc.
Oncopeptides AB
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 22 Sep, 2023
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more